Can India’s Syngene Best WuXi?
This article was originally published in PharmAsia News
Syngene's initial public offering (IPO) opened for subscription in India on 27 July, amid generally encouraging reviews and favorable comparisons with China's WuXi PharmaTech. Syngene is part of the Indian firm Biocon, and like WuXi provides a range of contract research services to the pharma industry.
You may also be interested in...
Tildrakizumab debuts in Japan, marking a key milestone for Sun Pharma, though heavyweight competitors including same class rival Skyrizi are already available on the market there.
Redirection of healthcare resources to tackle COVID-19 is posing huge challenges for TB care and researchers in the area. Companies like J&J have stepped in to support, among other aspects, innovative community-based solutions to ensure continuity of care for drug resistant-TB patients amid the pandemic.
The former CEO of Cipla’s India business is set to steer JB Chemicals and Pharmaceuticals, as the Indian firm embarks on a new phase of growth, backed by a revamped board, following its takeover by US private equity firm KKR.